Pregledni rad
cancer; thromboembolism; anticoagulant therapy; prevention
Luka Simetić
Puni tekst: hrvatski pdf 133 Kb
str. 39-44
preuzimanja: 0
citiraj
APA 6th Edition
Simetić, L. (2024). cancer; thromboembolism; anticoagulant therapy; prevention. Medicus, 33 (1 Tromboembolije), 39-39. Preuzeto s https://hrcak.srce.hr/321770
MLA 8th Edition
Simetić, Luka. "cancer; thromboembolism; anticoagulant therapy; prevention." Medicus, vol. 33, br. 1 Tromboembolije, 2024, str. 39-39. https://hrcak.srce.hr/321770. Citirano 31.10.2024.
Chicago 17th Edition
Simetić, Luka. "cancer; thromboembolism; anticoagulant therapy; prevention." Medicus 33, br. 1 Tromboembolije (2024): 39-39. https://hrcak.srce.hr/321770
Harvard
Simetić, L. (2024). 'cancer; thromboembolism; anticoagulant therapy; prevention', Medicus, 33(1 Tromboembolije), str. 39-39. Preuzeto s: https://hrcak.srce.hr/321770 (Datum pristupa: 31.10.2024.)
Vancouver
Simetić L. cancer; thromboembolism; anticoagulant therapy; prevention. Medicus [Internet]. 2024 [pristupljeno 31.10.2024.];33(1 Tromboembolije):39-39. Dostupno na: https://hrcak.srce.hr/321770
IEEE
L. Simetić, "cancer; thromboembolism; anticoagulant therapy; prevention", Medicus, vol.33, br. 1 Tromboembolije, str. 39-39, 2024. [Online]. Dostupno na: https://hrcak.srce.hr/321770. [Citirano: 31.10.2024.]
Puni tekst: engleski pdf 133 Kb
str. 39-39
preuzimanja: 0
citiraj
APA 6th Edition
Simetić, L. (2024). cancer; thromboembolism; anticoagulant therapy; prevention. Medicus, 33 (1 Tromboembolije), 39-39. Preuzeto s https://hrcak.srce.hr/321770
MLA 8th Edition
Simetić, Luka. "cancer; thromboembolism; anticoagulant therapy; prevention." Medicus, vol. 33, br. 1 Tromboembolije, 2024, str. 39-39. https://hrcak.srce.hr/321770. Citirano 31.10.2024.
Chicago 17th Edition
Simetić, Luka. "cancer; thromboembolism; anticoagulant therapy; prevention." Medicus 33, br. 1 Tromboembolije (2024): 39-39. https://hrcak.srce.hr/321770
Harvard
Simetić, L. (2024). 'cancer; thromboembolism; anticoagulant therapy; prevention', Medicus, 33(1 Tromboembolije), str. 39-39. Preuzeto s: https://hrcak.srce.hr/321770 (Datum pristupa: 31.10.2024.)
Vancouver
Simetić L. cancer; thromboembolism; anticoagulant therapy; prevention. Medicus [Internet]. 2024 [pristupljeno 31.10.2024.];33(1 Tromboembolije):39-39. Dostupno na: https://hrcak.srce.hr/321770
IEEE
L. Simetić, "cancer; thromboembolism; anticoagulant therapy; prevention", Medicus, vol.33, br. 1 Tromboembolije, str. 39-39, 2024. [Online]. Dostupno na: https://hrcak.srce.hr/321770. [Citirano: 31.10.2024.]
Sažetak
Malignancies are associated with an increased risk of thromboembolic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Hypercoagulable state is the main occurrence of malignant diseases. In addition to the malignant cells that secrete procoagulant factors, the hypercoagulable state is also influenced by the patient’s own characteristics (excess weight, diabetes, arterial hypertension, etc.), as well as the specific oncology therapy applied. The pre- and postoperative risk of thromboembolism is increased in patients with malignant diseases who undergo surgical treatment. In the treatment of thromboembolic events in patients with malignant diseases, low molecular weight heparins (LMWH) and DOACs are mainly used. Paradoxically, in addition to the increased risk of thromboembolic events, patients with malignant diseases also have an increased risk of treatment-related bleeding. An individual approach to the patient with a malignant disease is required, taking into account their underlying malignant disease, comorbidities and risks, in order to maximally protect him from thrombosis and minimize the risk of bleeding.
Ključne riječi
cancer; thromboembolism; anticoagulant therapy; prevention
Hrčak ID:
321770
URI
https://hrcak.srce.hr/321770
Datum izdavanja:
24.10.2024.
Podaci na drugim jezicima:
hrvatski
Posjeta: 0
*